| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/16/2002 | WO2002010158A3 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta |
| 05/16/2002 | WO2002007770A3 Polymeric conjugates of antitumor agents |
| 05/16/2002 | WO2002003871A8 Use of a liquid medicament in surgical high pressure liquid jet devices |
| 05/16/2002 | WO2002002640A3 Antibodies to human mcp-1 |
| 05/16/2002 | WO2002000680A3 Cationic steroid derivatives for gene delivery |
| 05/16/2002 | WO2001098290A3 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/16/2002 | WO2001097790A3 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 05/16/2002 | WO2001097789A3 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
| 05/16/2002 | WO2001096395A3 Biosynthetic oncolytic molecules and uses therefor |
| 05/16/2002 | WO2001096372A3 Zinc transporters proteins and their use in medicinal preparations |
| 05/16/2002 | WO2001092496A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/16/2002 | WO2001090313A3 METHODS FOR ASSAYING GENE IMPRINTING AND METHYLATED CpG ISLANDS |
| 05/16/2002 | WO2001088105A3 Production of dendritic cells from bone-marrow stem cells |
| 05/16/2002 | WO2001087333A3 Immune system stimulating means |
| 05/16/2002 | WO2001085789A3 Extracellular domain of ryk protein for regulating angiogenesis |
| 05/16/2002 | WO2001085144A3 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 05/16/2002 | WO2001083547A3 Anti-inflammatory compounds and uses thereof |
| 05/16/2002 | WO2001081622A8 Diagnosis of diseases associated with dna repair |
| 05/16/2002 | WO2001080879A3 Colorectal cancer vaccines and diagnosis |
| 05/16/2002 | WO2001079198A9 Pyrazoles for inhibiting protein kinase |
| 05/16/2002 | WO2001079155A3 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 05/16/2002 | WO2001076638A3 Compositions for drug delivery |
| 05/16/2002 | WO2001076597A3 A method of administering an antitumour compound using a polymer-camptothecin conjugate |
| 05/16/2002 | WO2001075109A3 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 05/16/2002 | WO2001074857A3 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 05/16/2002 | WO2001070663A3 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 05/16/2002 | WO2001070662A3 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 05/16/2002 | WO2001068144A3 Biodegradable immunomodulatory formulations and methods for use thereof |
| 05/16/2002 | WO2001066100A3 Pharmaceutical composition |
| 05/16/2002 | WO2001062668A3 Sulfur containing compounds |
| 05/16/2002 | WO2001058434A3 Diagnostic and therapeutic compositions and methods for affecting tumor growth using oxygen mimetic agents |
| 05/16/2002 | WO2001048163A3 Dioxygenases catalyzing the asymetric cleavage of beta-carotene |
| 05/16/2002 | WO2001047959A3 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 05/16/2002 | WO2001040521A3 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/16/2002 | WO2001032885A9 Human lipase |
| 05/16/2002 | WO2001032685A8 Gene expression directed by a super-psa promoter |
| 05/16/2002 | WO2001025408A9 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 05/16/2002 | US20020059652 Detecting modulators of liver cell propagation, cell differentiation and lymphocyte activity; obtain modulator, incubate with indicator, mix with culture monitor culture for adjustment in activity |
| 05/16/2002 | US20020058839 Methods and compositions for modulating alpha adrenergic receptor activity |
| 05/16/2002 | US20020058804 Includes an active therapeutic agent joined to a blocking moiety sensitive to the catalytic action of molecules having retro- aldol and retro-Michael catalytic activity; antitumor; anticarcinogenic agents |
| 05/16/2002 | US20020058795 Preferential particles for use in the transfer of macromolecules into cells; for use in gene therapy |
| 05/16/2002 | US20020058787 Mhc binding peptide oligomers and methods of use |
| 05/16/2002 | US20020058694 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents |
| 05/16/2002 | US20020058692 Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 05/16/2002 | US20020058687 For therapy and prohylaxis of inflammatory diseases including joint inflammation, Crohn's disease, and inflammatory bowel disease; respiratory diseases such as chronic obstructive pulmonary disease (COPD) including asthma, chronic bronchitis |
| 05/16/2002 | US20020058681 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 05/16/2002 | US20020058665 For use in cancer therapy |
| 05/16/2002 | US20020058661 Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors |
| 05/16/2002 | US20020058654 For therapy of uterine fibroids, endometriosis, polycystic ovarian disease, dysfunctional uterine bleeding, breast cancer and ovarian cancer; depletion of oocytes; spermatocyte depletion; for female and male contraception |
| 05/16/2002 | US20020058653 Administering cyclic polyamine compound to elevate white blood cell (WBC) count |
| 05/16/2002 | US20020058644 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/16/2002 | US20020058635 Purine L-nucleosides, analogs and uses thereof |
| 05/16/2002 | US20020058631 Dipeptide derivatives |
| 05/16/2002 | US20020058630 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 05/16/2002 | US20020058619 Ligand for vascular endothelial growth factor receptor |
| 05/16/2002 | US20020058616 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide) |
| 05/16/2002 | US20020058615 Endothelial specific targeting |
| 05/16/2002 | US20020058607 Containing the amino acid sequence (G/S/A/E)-L-F-(F/I/L); each - is a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash separating the alternative amino acids. |
| 05/16/2002 | US20020058336 Controlling cell binding; obtain target cell, incubate with substrate, monitor cell binding |
| 05/16/2002 | US20020058317 Process for the fusion of dendritic cells with abnormal tissue cells, in particular tumor cells and media for such a process |
| 05/16/2002 | US20020058264 Human regulatory molecules |
| 05/16/2002 | US20020058257 Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 |
| 05/16/2002 | US20020058077 Cancer chemotherapeutical and chemopreventive agent |
| 05/16/2002 | US20020058062 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism |
| 05/16/2002 | US20020058041 Kidney-specific tumor vaccine directed against kidney tumor antigen G-250 |
| 05/16/2002 | US20020058038 Specific octapeptides, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds and immune effector cells raised in response to presentation of these epitopes. |
| 05/16/2002 | US20020058036 Novel fibroblast growth factor and nucleic acids encoding same |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058034 Treating or ameliorating an autoimmune condition, an allergic reaction or asthma |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/16/2002 | US20020058024 Modulators of the function of receptors of the TNF/NGF receptor family and other proteins |
| 05/16/2002 | US20020058022 Novel compounds |
| 05/16/2002 | US20020058019 Simultaneous stimulation and concentration of cells |
| 05/16/2002 | US20020058007 Targeted alpha particle therapy using actinium-225 conjugates |
| 05/16/2002 | DE10056136A1 Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
| 05/16/2002 | CA2429000A1 Adjuvant combination formulations |
| 05/16/2002 | CA2428179A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | CA2428176A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | CA2428161A1 Substances causing differentiation |
| 05/16/2002 | CA2428141A1 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis of inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases |
| 05/16/2002 | CA2427757A1 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | CA2427622A1 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | CA2426730A1 Calcilytic compounds |
| 05/16/2002 | CA2426037A1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | CA2425829A1 Proteases |
| 05/16/2002 | CA2396638A1 Anticancer agent |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205191A1 Targeted modification of intracellular compounds |
| 05/15/2002 | EP1204868A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 05/15/2002 | EP1204754A2 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby |
| 05/15/2002 | EP1204748A2 New g-protein coupled receptor and dna sequences thereof |
| 05/15/2002 | EP1204745A2 Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
| 05/15/2002 | EP1204744A1 Isolated peptide of the horny layer and use thereof |
| 05/15/2002 | EP1204743A2 Methods of inhibiting cancer cells with adnf iii antisense oligonucleotides |
| 05/15/2002 | EP1204742A2 Oligonucleotides for inhibiting the expression of human eg5 |
| 05/15/2002 | EP1204683A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 05/15/2002 | EP1204682A2 Compositions and methods for the treatment of tumors |
| 05/15/2002 | EP1204681A2 Helical cytokine zalpha48 |
| 05/15/2002 | EP1204666A1 Hexahydropyrrolo[1,2-c]pyrimidines as antiviral, antifungal and/or antitumor agents |
| 05/15/2002 | EP1204656A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |